Trimetazidine inhibits cardiomyocyte apoptosis in a rabbit model of ischemia-reperfusion

Translational Research

Volumn 149, Issue 3, 2007, Pages 152-160

  Ruixing, Yin ^a   Wenwu, Liang ^a   Al Ghazali, Rasheed ^a  

^a First Affiliated Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CYTOCHROME C; MALONALDEHYDE; SUPEROXIDE DISMUTASE; TRIMETAZIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME BLOOD LEVEL; ENZYME RELEASE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEMODYNAMICS; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRESSURE MEASUREMENT; PRIORITY JOURNAL; RABBIT; SYSTOLIC BLOOD PRESSURE;

ANIMALS; APOPTOSIS; BLOOD PRESSURE; MALONDIALDEHYDE; MYOCARDIAL REPERFUSION INJURY; MYOCYTES, CARDIAC; RABBITS; SUPEROXIDE DISMUTASE; TRIMETAZIDINE; VASODILATOR AGENTS;

EID: 33847051689     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2006.11.004     Document Type: Article

References (52)

1. Fliss H., and Gattinger D. Apoptosis in ischemic and reperfused rat myocardium. Circ Res 79 (1996) 949-956
2. Galang N., Sasaki H., and Maulik N. Apoptotic cell death during ischemia/reperfusion and its attenuation by antioxidant therapy. Toxicol 148 (2000) 111-118
3. Gottlieb R.A., Burleson K.O., Kloner R.A., Babior B.M., and Engler R.L. Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest 94 (1994) 1621-1628
4. Freude B., Masters T.N., Robicsek F., Fokin A., Kostin S., Zimmermann R., et al. Apoptosis is initiated by myocardial ischemia and executed during reperfusion. J Mol Cell Cardiol 32 (2000) 197-208
5. Singh B. Mechanism of action of a novel metabolically active antianginal agent (trimetazidine) delineated by PET. J Am Coll Cardiol 27 (1996) 132A
6. Mody F.V., Singh B.N., Mohiuddin I.H., Coyle K.B., Buxton D.B., Hansen H.W., et al. Trimetazidine-induced enhancement of myocardial glucose utilization in normal and ischemic myocardial tissue: an evaluation by positron emission tomography. Am J Cardiol 82 (1998) 42-49K
7. Reymond F., Steyaert G., Carrupt P.A., Morin D., Tillement J.P., Girault H.H., et al. The pH-partition profile of the anti-ischemic drug trimetazidine may explain its reduction of intracellular acidosis. Pharm Res 16 (1999) 616-624
8. 2+ regulation by trimetazidine during cardiac cell acidosis. Cardiovasc Drugs Ther 1 (1988) 677-686
9. El Banani H., Bernard M., Baetz D., Cabanes E., Cozzone P., Lucien A., et al. Changes in intracellular sodium and pH during ischaemia-reperfusion are attenuated by trimetazidine. Comparison between low- and zero-flow ischaemia. Cardiovasc Res 47 (2000) 688-696
10. Salducci M.D., Chauvet-Monges A.M., Tillement J.P., Albengres E., Testa B., Carrupt P., et al. Trimetazidine reverses calcium accumulation and impairment of phosphorylation induced by cyclosporine A in isolated rat liver mitochondria. J Pharmacol Exp Ther 277 (1996) 417-422
11. Guarnieri C., Finelli C., Zini M., and Muscari C. Effects of trimetazidine on the calcium transport and oxidative phosphorylation of isolated rat heart mitochondria. Basic Res Cardiol 92 (1997) 90-95
12. Blardi P., de Lalla A., Volpi L., Auteri A., and Di Perri T. Increase of adenosine plasma levels after oral trimetazidine: a pharmacological preconditioning?. Pharmacol Res 45 (2002) 69-72
13. Ikizler M., Dernek S., Sevin B., and Kural T. Trimetazidine improves recovery during reperfusion in isolated rat hearts after prolonged ischemia. Anadolu Kardiyol Derg 3 (2003) 303-308
14. Di Pasquale P., Lo Verso P., Bucca V., Cannizzaro S., Scalzo S., Maringhini G., et al. Effects of trimetazidine administration before thrombolysis in patients with anterior myocardial infarction: short-term and long-term results. Cardiovasc Drugs Ther 13 (1999) 423-428
15. Veitch K., Maisin L., and Hue L. Trimetazidine effects on the damage to mitochondrial functions caused by ischemia and reperfusion. Am J Cardiol 76 (1995) 25-30B
16. Spedding M., Tillement J.P., Morin D., and Le Ridant A. Medicines interacting with mitochondria: anti-ischemic effects of trimetazidine. Therapie 54 (1999) 627-635
17. Argaud L., Gomez L., Gateau-Roesch O., Couture-Lepetit E., Loufouat J., Robert D., et al. Trimetazidine inhibits mitochondrial permeability transition pore opening and prevents lethal ischemia-reperfusion injury. J Mol Cell Cardiol 39 (2005) 893-899
18. Gambert S., Vergely C., Filomenko R., Moreau D., Bettaieb A., Opie L.H., et al. Adverse effects of free fatty acid associated with increased oxidative stress in postischemic isolated rat hearts. Mol Cell Biochem 283 (2006) 147-152
19. Mody F.V., Singh B.N., Mohiuddin I.H., Coyle K.B., Buxton D.B., Hansen H.W., et al. Trimetazidine-induced enhancement of myocardial glucose utilization in normal and ischemic myocardial tissue: an evaluation by positron emission tomography. Am J Cardiol 82 (1998) 42-49K
20. Maridonneau Parini I., and Harpey C. Effects of trimetazidine on membrane damage reduced by oxygen free radicals in human red cells. Br J Clin Pharmacol 20 (1985) 148-151
21. Maupoil V., Rochette L., Tabard A., Clauser P., and Harpey C. Direct measurement of free radical generation in isolated rat heart by electron paramagnetic resonance spectroscopy: effect of trimetazidine. Adv Exp Med Biol 264 (1990) 373-376
22. Williams F.M., Tanda K., Kus M., and Williams T.J. Trimetazidine inhibits neutrophil accumulation after myocardial ischaemia and reperfusion in rabbits. J Cardiovasc Pharmacol 22 (1993) 828-833
23. Jordan J.E., Zhao Z.Q., and Vinten-Johansen J. The role of neutrophils in myocardial ischemia-reperfusion injury. Cardiovasc Res 43 (1999) 860-878
24. Fabiani J.N., Farah B., Vuilleminot A., Lecompate T., Emerit I., Chardigny C., et al. Chromosomal aberrations and neutrophil activation induced by reperfusion in the ischaemic human heart. Eur Heart J 14 Suppl G (1993) 12-17
25. Tritto I., Wang P., Kuppusamy P., Giraldez R., Zweier J.L., and Ambrosio G. The anti-anginal drug trimetazidine reduces neutrophil-mediated cardiac reperfusion injury. J Cardiovasc Pharmacol 46 (2005) 89-98
26. Mehrotra T.N., and Bassadone E.T. Trimetazidine in the treatment of angina pectoris. Br J Clin Pract 21 (1967) 553-554
27. Detry J.M., and Leclerq B.S. Trimetazidine European multicenter study vs. propranolol in stable angina pectoris: contribution of Holter electrocardiographic ambulatory monitoring. Am J Cardiol 76 (1995) 8-11B
28. Chazov E.I., Lepakchin V.K., Zharova E.A., Fitilev S.B., Levin A.M., Rumiantzeva E.G., et al. Trimetazidine in Angina Combination Therapy--the TACT study: trimetazidine versus conventional treatment in patients with stable angina pectoris in a randomized, placebo-controlled, multicenter study. Am J Ther 12 (2005) 35-42
29. Fabiani J.N., Ponzio O., Emerit I., Massonet-Castel S., Paris M., Chevalier P., et al. Cardioprotective effect of trimetazidine during coronary artery graft surgery. J Cardiovasc Surg (Torino) 33 (1992) 486-491
30. Vedrinne J.M., Vedrinne C., Bompard D., Lehot J.J., Boissel J.P., and Champsaur G. Myocardial protection during coronary artery bypass graft surgery: a randomized, double-blind, placebo-controlled study with trimetazidine. Anesth Analg 82 (1996) 712-718
31. Steg P.G., Grollier G., Gallay P., Morice M., Karrillon G.J., Benamer H., et al. A randomized double-blind trial of intravenous trimetazidine as adjunctive therapy to primary angioplasty for acute myocardial infarction. Int J Cardiol 77 (2001) 263-273
32. Kober G., Buck T., Sievert H., and Vallbracht C. Myocardial protection during percutaneous transluminal coronary angioplasty: effects of trimetazidine. Eur Heart J 13 (1992) 1109-1115
33. Beygui F. Trimetazidine as adjunctive therapy to primary PTCA for acute myocardial infarction. Rev Port Cardiol 19 (2000) V31-V34
34. Polonski L., Dec I., Wojnar R., and Wilczek K. Trimetazidine limits the effects of myocardial ischaemia during percutaneous coronary angioplasty. Curr Med Res Opin 18 (2002) 389-396
35. Belardinelli R. Trimetazidine and the contractile response of dysfunctional myocardium in ischaemic cardiomyopathy. Rev Port Cardiol 19 (2000) V35-V39
36. Lu C., Dabrowski P., Fragasso G., and Chierchia S.L. Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease. Am J Cardiol 82 (1998) 898-901
37. Wang N., Minatoguchi S., Chen X., Uno Y., Arai M., Lu C., et al. Antidiabetic drug miglitol inhibits myocardial apoptosis involving decreased hydroxyl radical production and Bax expression in an ischaemia/reperfusion rabbit heart. Br J Pharmacol 142 (2004) 983-990
38. Iwatsubo K., Minamisawa S., Tsunematsu T., Nakagome M., Toya Y., Tomlinson J.E., et al. Direct inhibition of type 5 adenylyl cyclase prevents myocardial apoptosis without functional deterioration. J Biol Chem 279 (2004) 40938-40945
39. Sun Y., Oberley L.W., and Li Y. A simple method for clinical assay of superoxide dismutase. Clin Chem 34 (1988) 497-500
40. Draper H.H., and Hadley M. Malondialdehyde determination as index of lipid peroxidation. Methods Enzymol 186 (1990) 421-431
41. Harpey C., Clauser P., Labrid C., Freyria J.L., and Poirier J.P. Trimetazidine, a cellular anti-ischemic agent. Cardiovasc Drug Rev 6 (1989) 292-312
42. Sellier P., Audouin P., Payen B., Corona P., Duong T.C., and Ourbak P. Acute effects of trimetazidine evaluated by exercise testing. Eur J Clin Pharmacol 33 (1987) 205-207
43. Pornin M., Harper C., Allal J., Sellier P., and Ourbak P. Lack of effects of trimetazidine on systemic hemodynamics in patients with coronary artery disease: a placebo-controlled study. Clin Trials Metaanal 29 (1994) 49-56
44. El-Kady T., El-Sabban K., Gabaly M., Sabry A., and Abdel-Hady S. Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemic cardiomyopathy: a 24-month study. Am J Cardiovasc Drugs 5 (2005) 271-278
45. Fedorova T.A., Il'ina IuV., Sotnikova T.I., Rybakova M.K., and Loshchits N.V. Clinical and hemodynamic efficacy of selective beta-blocker bisoprolol and cytoprotector trimetazidine in the treatment of chronic cardiac failure in patients with ischemic heart disease. Ter Arkh 76 (2004) 62-68
46. Noble M.I., Belcher P.R., and Drake-Holland A.J. Limitation of infarct size by trimetazidine in the rabbit. Am J Cardiol 76 (1995) 41-4B
47. Thompson C.B. Apoptosis in the pathogenesis and treatment of disease. Science 267 (1995) 1456-1462
48. Entman M.L., Michael L., Rossen R.D., Dreyer W.J., Anderson D.C., Taylor A.A., et al. Inflammation in the course of early myocardial ischemia. FASEB J 5 (1991) 2529-2537
49. Barsotti A., and Di Napoli P. Trimetazidine and cardioprotection during ischemia-reperfusion. Ital Heart J 5 (2004) 29-36S
50. Kantor P., Lucien A., Kozak R., and Lopaschuk G.D. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 86 (2000) 580-588
51. MacInnes A., Fairman D.A., Binding P., Rhodes J., Wyatt M.J., Phelan A., et al. The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 93 (2003) e26-e32
52. Lopaschuk G.D., Barr R., Thomas P.D., and Dyck J.R. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase. Circ Res 93 (2003) e33-e37